Motor phenotype of LRRK2-associated Parkinson's disease: A tunisian longitudinal study

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 253-258

  Nabli, Fatma ^a   Ben Sassi, Samia ^a   Amouri, Rim ^a   Duda, John E ^b   Farrer, Matthew J ^c   Hentati, Fayçal ^a  

^a Institut National de Neurologie Tunisia   (Tunisia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

G2019S mutation; Longitudinal study; LRRK2 gene; PARK8; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GAIT DISORDER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; TUNISIAN; UNIFIED PARKINSON DISEASE RATING SCALE; GAIT; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PHYSIOLOGY; TUNISIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GAIT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; TUNISIA;

EID: 84922260502     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26097     Document Type: Article

References (23)

1. Dachsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 2010;67:542-547.
2. Sundal C, Fujioka S, Uitti RJ, Wszolek ZK. Autosomal dominant Parkinson's disease. Parkinsonism Relat Disord 2012;18:S7-S10.
3. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. Geriatr Psychiatry Neurol 2010;23:228-242.
4. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Samaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2009;11:322-325.
5. Lesage S, Patin E, Condroyer C, et al. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum Mol Genet 2010;19:1998-2004.
6. Trinh J, Amouri R, Duda JE, et al. A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G201, 9S parkinsonism. Neurobiol Aging 2014;35:1125-1131.
7. Hulihan M, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet 2008;7:591-594.
8. Alcalay RN, Mejia-Santana H, Tang MX et al. Motor phenotype of LRRK2 G2019S carriers in early onset Parkinson disease. Arch Neurol 2009;66:1517-1522.
9. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
10. Wider C, Pollo C, Bloch J. Long term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008;14:114-119.
11. Nishioka K, Kefi M, Jasinska-Myga B, et al. A comparative study of LRRK2, PINK1, and genetically undefined familial Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81:391-395.
12. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case control study. Lancet Neurol 2008;7:583-590.
13. Orr-Urtreger A, Shifrin C, Rosovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69:1595-1602.
14. Uitti RJ, Baba Y, Whaley NR, Wszlek ZK, Putzke JD. Parkinson disease: handedness predicts asymmetry. Neurology 2005;64:1925-1930.
15. Clarimon J, Pagonabarraga J, Paisan- Ruiz C. Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Mov Disord 2008;23:518-523.
16. Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK. LRRK2 gene and tremor dominant Parkinsonism. Arch Neurol 2006;63:1346-1347.
17. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
18. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: A population-based study. Neurology 2005;65:1436-1441.
19. Post B, Muslimovic D, Geloven NV, Speelman JD, Schmand B, de Haan RJ. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 2011;26:449-456.
20. Hilker R, Schweitzer K, Coburger S. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity. Arch Neurol 2005;62:378-382.
21. Louis ED, Tang MX, Cote I, Alfaro B, Mejia H, Marder K. Progression of Parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
22. Hely MA, Morris JG, Reid WG. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995;92:455-463.
23. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 2000;15:479-484.